Tag: Alzheimer’s
FDA Approves Aduhelm for Alzheimer Disease
Agency says it has granted approval on the condition that drug maker Biogen conduct a new clinical trial
Donanemab Studied in Early Symptomatic Alzheimer Disease
Slightly less cognitive and functional decline seen with donanemab versus placebo at 76 weeks in phase 2 trial
AAN: Prior Psych Diagnosis Tied to Younger Age of Alzheimer Onset
Findings based on data from retrospective chart review of patients at tertiary specialty memory care center
Many Non-Whites Experience Discrimination in Alzheimer Disease Care
Overall, 36, 19, and 18 percent of Black, Hispanic, Asian Americans, respectively, believe discrimination is barrier to receiving care
Prediabetes, Type 2 Diabetes Tied to Poorer Brain Health
Higher risk for cognitive decline, vascular dementia, Alzheimer disease seen with high blood glucose
White Matter Hyperintensities Characterized in Dementia
Association seen for larger volumes of white matter hyperintensities with disease severity, but not vascular risk, in bvFTD
Half of Alzheimer Disease Dementia Cases Are Mild
Among Framingham Heart Study participants, one in five cases were severe
Memory Preserved in Rare Aphasia Tied to Alzheimer Disease
Decline in language function, but not episodic memory, seen for primary progressive aphasia associated with Alzheimer disease
Experimental Drug for Alzheimer Disease Shows Promise
After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques
Residential Care Community Characteristics Vary by Dementia Prevalence
Higher prevalence of depression, need for assistance with activities of daily living seen for high proportion of residents with dementia
